{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:47:00Z","timestamp":1767134820515,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd006790.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T00:00:00Z","timestamp":1442188800000}}],"reference-count":86,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006790.pub3","type":"journal-article","created":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T10:56:28Z","timestamp":1442228188000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Type I interferons for induction of remission in ulcerative colitis"],"prefix":"10.1002","volume":"2015","author":[{"given":"Yongjun","family":"Wang","sequence":"first","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric I","family":"Benchimol","sequence":"additional","affiliation":[{"name":"The Children's Hospital of Eastern Ontario; CHEO Inflammatory Bowel Disease Centre, Division of Gastroenterology Hepatology & Nutrition; 401 Smyth Road Ottawa ON Canada K1H 8L1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Marie","family":"Griffiths","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children; Division of Gastroenterology, Hepatology & Nutrition; 555 University Ave. Toronto ON Canada M5G 1X8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A Hillary","family":"Steinhart","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital; Department of Medicine, Division of Gastroenterology; Room 445, 600 University Avenue Toronto ON Canada M5G 1X5"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"University Of Calgary; Calgary AB Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia H","family":"Seow","sequence":"additional","affiliation":[{"name":"University of Calgary; Department of Medicine; TRW Building Rm 6D18 3280 Hospital Drive NW Calgary AB Canada T2N 4Z6"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,9,14]]},"reference":[{"issue":"Suppl V","key":"10.1002\/14651858.CD006790.pub3-BIB0001|cit1","first-page":"A286","article-title":"An open, randomized study comparing systemic interferon-a-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis","volume":"45","author":"Madsen","year":"1999","journal-title":"Gut"},{"issue":"6","key":"10.1002\/14651858.CD006790.pub3-BIB0002|cit2","first-page":"1807","article-title":"An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis","volume":"96","author":"Madsen","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0003|cit3","first-page":"S102","article-title":"Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country-enrollment site in a phase IIa study with interferon-\u00df-1a","volume":"5","author":"Mannon","year":"2011","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD006790.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"S468","DOI":"10.14309\/00000434-201010001-01274","article-title":"Secondary efficacy analysis from a phase IIa multicenter study with interferon-\u00df-1a for induction of clinical response in active moderate to severe ulcerative colitis","volume":"105","author":"Mannon","year":"2010","journal-title":"American Journal of Gatroenterology"},{"key":"10.1002\/14651858.CD006790.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"S446","DOI":"10.14309\/00000434-201010001-01216","article-title":"Interferon-\u00df-1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study","volume":"105","author":"Mannon","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0006|cit6","first-page":"S69","article-title":"Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post-hoc analysis in a phase 2a study with interferon-\u00df-1a","volume":"5","author":"Mannon","year":"2011","journal-title":"Journal of Crohn's and Colitis"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0007|cit7","first-page":"S94","article-title":"Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon-\u00df-1a in ulcerative colitis","volume":"5","author":"Mannon","year":"2011","journal-title":"Journal of Crohn's and Colitis"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0008|cit8","first-page":"S84","article-title":"Is there a difference between self-assessed patient-reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon-\u00df-1a","volume":"5","author":"Mannon","year":"2011","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD006790.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1093\/ibd\/17.supplement1.S54b","article-title":"Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon-B-1a","volume":"17","author":"Miner","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD006790.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1093\/ibd\/17.supplement1.S55","article-title":"Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon-B-1a","volume":"17","author":"Miner","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD006790.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1093\/ibd\/17.supplement1.S36","article-title":"Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon-B-1a in ulcerative colitis","volume":"17","author":"Miner","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD006790.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S433","DOI":"10.14309\/00000434-201010001-01189","article-title":"Safety analysis from a phase IIa multicenter study with interferon-\u00df-1a in active moderate to severe ulcerative colitis","volume":"105","author":"Miner","year":"2010","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD006790.pub3-BIB0013|cit13","unstructured":"NCT00616434 A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of Avonex\u00ae in subjects with moderate to severe ulcerative colitis https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00616434"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0014|cit14","first-page":"S72","article-title":"Is elevated CRP a predictor of efficacy in ulcerative colitis? Post-hoc analysis from a placebo-controlled study with interferon-\u00df-1a","volume":"5","author":"Reinisch","year":"2011","journal-title":"Journal of Crohn's and Colitis"},{"issue":"6","key":"10.1002\/14651858.CD006790.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1542-3565(05)00208-9","article-title":"Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial","volume":"3","author":"Musch","year":"2005","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD006790.pub3-BIB0016|cit16","first-page":"A431","article-title":"A phase II placebo-controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta-1a in patients with ulcerative colitis","volume":"122","author":"Musch","year":"2002","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD006790.pub3-BIB0017|cit17","first-page":"705","article-title":"Results of a randomised, double-blind, placebo-controlled, multi-centre, phase-II study to test the effectivity and tolerance of Interferon-beta-1a (CHO-beta) [rIFN-beta-1a] in patients with ulcerative colitis","volume":"40","author":"Musch","year":"2002","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"9","key":"10.1002\/14651858.CD006790.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/gut.52.9.1286","article-title":"Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study","volume":"52","author":"Nikolaus","year":"2003","journal-title":"Gut"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD006790.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"A454","DOI":"10.1016\/S0016-5085(01)82251-4","article-title":"Recombinant human interferon-beta (IFNb-1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC)","volume":"120","author":"Nikolaus","year":"2001","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD006790.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2036.2008.03778.x","article-title":"Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis","volume":"28","author":"Pena-Rossi","year":"2008","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD006790.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"A62","DOI":"10.1016\/S0016-5085(03)80305-0","article-title":"A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis","volume":"124","author":"Tilg","year":"2003","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD006790.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1136\/gut.52.12.1728","article-title":"A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis","volume":"52","author":"Tilg","year":"2003","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD006790.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2005.02556.x","article-title":"Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study","volume":"22","author":"Bargiggia","year":"2005","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD006790.pub3-BIB0024|cit24","first-page":"1323","article-title":"Interferon alpha-2A (roferon) as a treatment of inflammatory bowel disease in children and adolescents","volume":"371B","author":"Hadziselimovic","year":"1995","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"2","key":"10.1002\/14651858.CD006790.pub3-BIB0025|cit25","first-page":"31","article-title":"[Interferon status of patients with non-specific ulcerous colitis and its correction with interferon inducers]","volume":"74","author":"Maev","year":"2002","journal-title":"Terapevticheski\u012d Arkhiv"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1873-9954(10)70065-3","article-title":"A phase IIa study of AVONEX (interferon-B-1a) in ulcerative colitis (UC): Integrating basic immunology and human pilot study results","volume":"4","author":"Cataldi","year":"2010","journal-title":"Journal of Crohn's and Colitis Supplements"},{"issue":"4","key":"10.1002\/14651858.CD006790.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/gut.2010.226860","article-title":"Suppression of inflammation in ulcerative colitis by interferon-\u00df-1a is accompanied by inhibition of IL-13 production","volume":"60","author":"Mannon","year":"2011","journal-title":"Gut"},{"issue":"7","key":"10.1002\/14651858.CD006790.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1046\/j.1365-2036.2002.01264.x","article-title":"Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis - an open long-term pilot trial","volume":"16","author":"Musch","year":"2002","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"12","key":"10.1002\/14651858.CD006790.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1055\/s-2007-963378","article-title":"Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial","volume":"45","author":"Musch","year":"2007","journal-title":"Zeitschrift f\u00fcr Gastroenterologie"},{"issue":"7","key":"10.1002\/14651858.CD006790.pub3-BIB0030|cit30","first-page":"597","article-title":"Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis","volume":"7","author":"S\u00fcmer","year":"1995","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"9139","key":"10.1002\/14651858.CD006790.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","volume":"352","author":"Anonymous","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD006790.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1212\/WNL.56.12.1628","article-title":"PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS","volume":"56","author":"Anonymous","year":"2001","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD006790.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1089\/10799900260475696","article-title":"A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis","volume":"22","author":"Antonetti","year":"2002","journal-title":"Journal of Interferon & Cytokine Research"},{"issue":"9573","key":"10.1002\/14651858.CD006790.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD006790.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00005176-199605000-00006","article-title":"Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis","volume":"22","author":"Beattie","year":"1996","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/ajg.2014.357","article-title":"Treatment of IBD: where we are and where we are going","volume":"110","author":"Bernstein","year":"2015","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/BOR.0b013e328010c547","article-title":"Syndromes and complications of interferon therapy","volume":"19","author":"Borg","year":"2007","journal-title":"Current Opinion in Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD006790.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nri1132","article-title":"The immunological and genetic basis of inflammatory bowel disease","volume":"3","author":"Bouma","year":"2003","journal-title":"Nature reviews. Immunology"},{"issue":"4","key":"10.1002\/14651858.CD006790.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1189\/jlb.71.4.565","article-title":"Interferon-alpha as an immunotherapeutic protein","volume":"71","author":"Brassard","year":"2002","journal-title":"Journal of Leukocyte Biology"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12101","article-title":"Interferon induction and function at the mucosal surface","volume":"255","author":"Durbin","year":"2013","journal-title":"Immunological Reviews"},{"issue":"7109","key":"10.1002\/14651858.CD006790.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006790.pub3-BIB0042|cit42","first-page":"294","article-title":"The history of genetics in inflammatory bowel disease","volume":"27","author":"Ek","year":"2014","journal-title":"Annals of Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD006790.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD006790.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"Journal of Clinical Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD006790.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1365-2036.2004.02170.x","article-title":"Review article: pegylated interferons: chemical and clinical differences","volume":"20","author":"Foster","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pharmthera.2012.03.006","article-title":"Pharmacology and therapeutic potential of interferons","volume":"135","author":"George","year":"2012","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.autrev.2013.06.004","article-title":"Innate and adaptive immunity in inflammatory bowel disease","volume":"13","author":"Geremia","year":"2014","journal-title":"Autoimmunity Reviews"},{"issue":"8","key":"10.1002\/14651858.CD006790.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/gut.2005.090134","article-title":"Interfering with interferons in inflammatory bowel disease","volume":"55","author":"Ghosh","year":"2006","journal-title":"Gut"},{"issue":"1-2","key":"10.1002\/14651858.CD006790.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jneuroim.2007.01.011","article-title":"Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response","volume":"185","author":"Graber","year":"2007","journal-title":"Journal of Neuroimmunology"},{"issue":"3","key":"10.1002\/14651858.CD006790.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/0016-5085(89)90905-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"issue":"7650","key":"10.1002\/14651858.CD006790.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006790.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.MIB.0000195385.19268.68","article-title":"Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities","volume":"12 Suppl 1","author":"Hanauer","year":"2006","journal-title":"Inflammatory Bowel Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006790.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00535-009-0191-y","article-title":"The role of infection in the aetiology of inflammatory bowel disease","volume":"45","author":"Hansen","year":"2010","journal-title":"Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD006790.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","article-title":"Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution","volume":"129","author":"Heller","year":"2005","journal-title":"Gastroenterology"},{"issue":"7414","key":"10.1002\/14651858.CD006790.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006790.pub3-BIB0056|cit56","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"23","key":"10.1002\/14651858.CD006790.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMct061675","article-title":"Peginterferon and ribavirin for chronic hepatitis C","volume":"355","author":"Hoofnagle","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nature reviews. Immunology"},{"issue":"2","key":"10.1002\/14651858.CD006790.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/cei.12409","article-title":"The route to pathologies in chronic inflammatory diseases characterized by T helper type 2 immune cells","volume":"178","author":"Jovanovic","year":"2014","journal-title":"Clinical and Experimental Immunology"},{"issue":"8","key":"10.1002\/14651858.CD006790.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/acn3.84","article-title":"Immunomodulatory activity of interferon-beta","volume":"1","author":"Kasper","year":"2014","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006790.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3748\/wjg.v20.i5.1238","article-title":"Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases","volume":"20","author":"Ko","year":"2014","journal-title":"World Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003617.pub2","article-title":"Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C","author":"Koretz","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8706","key":"10.1002\/14651858.CD006790.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0140-6736(90)91521-B","article-title":"Preliminary report: cyclosporin in treatment of severe active ulcerative colitis","volume":"336","author":"Lichtiger","year":"1990","journal-title":"Lancet"},{"issue":"20","key":"10.1002\/14651858.CD006790.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1007\/s00018-012-0989-2","article-title":"Type I IFN-mediated regulation of IL-1 production in inflammatory disorders","volume":"69","author":"Ludigs","year":"2012","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"6","key":"10.1002\/14651858.CD006790.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0168-8278(01)00022-8","article-title":"Ulcerative colitis associated with interferon treatment for chronic hepatitis C","volume":"34","author":"Mavrogiannis","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD006790.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","article-title":"Side effects of high-dose interferon therapy for chronic hepatitis C","volume":"25","author":"Okanoue","year":"1996","journal-title":"Journal of Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD006790.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3109\/00365527809182199","article-title":"A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis","volume":"13","author":"Powell-Tuck","year":"1978","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"6666","key":"10.1002\/14651858.CD006790.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","article-title":"Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial","volume":"298","author":"Rachmilewitz","year":"1989","journal-title":"BMJ"},{"issue":"23","key":"10.1002\/14651858.CD006790.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"26","key":"10.1002\/14651858.CD006790.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006790.pub3-BIB0071|cit71","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"8","key":"10.1002\/14651858.CD006790.pub3-BIB0072|cit72","first-page":"971","article-title":"An index of disease activity in patients with ulcerative colitis","volume":"87","author":"Seo","year":"1992","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaci.2005.03.016","article-title":"Differential effects of IFN-alpha on the expression of various TH2 cytokines in human CD4+ T cells","volume":"116","author":"Shibuya","year":"2005","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"7","key":"10.1002\/14651858.CD006790.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/1097-0142(19911001)68:7<1538::AID-CNCR2820680714>3.0.CO;2-2","article-title":"Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha","volume":"68","author":"Sparano","year":"1991","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD006790.pub3-BIB0075|cit75","first-page":"438","article-title":"Acute ulcerative colitis during successful interferon\/ribavirin treatment for chronic hepatitis","volume":"54","author":"Sprenger","year":"2005","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD006790.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/BF02355061","article-title":"Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C","volume":"31","author":"Tada","year":"1996","journal-title":"Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD006790.pub3-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000478.pub3","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","author":"Timmer","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006790.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2036.2006.03070.x","article-title":"Review article: induction therapy for patients with active ulcerative colitis","volume":"24 Suppl 1","author":"Travis","year":"2006","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD006790.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/gutjnl-2011-300486","article-title":"Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)","volume":"61","author":"Travis","year":"2012","journal-title":"Gut"},{"issue":"4947","key":"10.1002\/14651858.CD006790.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"British Medical Journal"},{"issue":"11","key":"10.1002\/14651858.CD006790.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1111\/j.1572-0241.2002.07029.x","article-title":"Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis","volume":"97","author":"Tsukada","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD006790.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ibd.20152","article-title":"Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C","volume":"13","author":"Tursi","year":"2007","journal-title":"Inflammatory Bowel Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"issue":"11","key":"10.1002\/14651858.CD006790.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/gut.2006.105197","article-title":"A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin","volume":"55","author":"Watanabe","year":"2006","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD006790.pub3-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006790.pub2","article-title":"Type I interferons for induction of remission in ulcerative colitis","author":"Seow","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006790.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T22:20:08Z","timestamp":1691965208000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006790.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,9,14]]},"references-count":86,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006790.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,14]]}}}